VivoSeq
Other

Infections

6

Pipeline Programs↗

18

Active Trials↗

19

Companies Involved↗

Infections is an early-stage landscape with 6 programs across 19 companies. The most active players are GSK, Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd, Pfizer. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

5 programs

Phase 1Y

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

1 program

Phase 1Pfizer logo

Pfizer

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalC

Curatek Pharmaceuticals, LLC

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Vaccine

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSSmall molecule229%

Vaccine leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

128

clinical trials

Completed86 · 67%
Unknown status10 · 8%
Recruiting9 · 7%
Withdrawn7 · 5%
Not yet recruiting7 · 5%
Terminated6 · 5%
Other3 · 2%

Clinical Trials

Trial Activity

128 trials

Characteristics and Outcomes of TB and HIV Co-infections
Recruiting·—·N/A·NCT06531772·100 enrolled
Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06595979·222 enrolled
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
Recruiting·MMansoura University·Phase 2/3·NCT06843668·120 enrolled
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
Recruiting·IIndiana University·Phase 4·NCT06982105·100 enrolled
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Recruiting·XX4 Pharmaceuticals·Phase 3·NCT06056297·176 enrolled
Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals
Recruiting·—·N/A·NCT06973174·40 enrolled
Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections
Recruiting·SShandong University·N/A·NCT06711575·300 enrolled
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Recruiting·—·Phase 1·NCT04013802·47 enrolled
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006150·600 enrolled
Pentaglobin in CRE and PA Neutropenic Infections
Active, not recruiting·GGruppo Italiano Trapianto di Midollo Osseo·Phase 2·NCT03494959·120 enrolled
Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Not yet recruiting·SSichuan Provincial People's Hospital·N/A·NCT06210542·50 enrolled
Comparing Tigecycline Vs. Colistimethate in CNS Infections
Not yet recruiting·—·N/A·NCT06702943·70 enrolled
Oritavancin for CIED Infections With MDR Gram-positive Cocci
Not yet recruiting·MMedical University of Silesia·N/A·NCT07013552·100 enrolled
Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
Not yet recruiting·JJosé Raimundo Araujo de Azevedo·N/A·NCT06305455·200 enrolled
Correlation Between Carbapenemase-Producing Enterobacterales Load, Environmental Contamination, and Transmission in Critical Care Units
Not yet recruiting·HHospital Italiano de Buenos Aires·N/A·NCT07685132·60 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)